Crystalys Therapeutics — Valuation, Funding & Investors

Recent changes

Jul 22, 2026Jul 22, 2026Raised $130M Series B citybiz

Funding History

1 event · sources dated per row

Date	Event	Amount	Valuation	Investors	Source
Jul 22, 2026	Series B	$130M	—		Pulse story

Latest Pulse

Jul 22, 2026Crystalys Raises $130M to Push Gout Drug Through Phase 3Crystalys Therapeutics raised a $130 million Series B led by Frazier Life Sciences to fund global Phase 3 trials of dotinurad, an oral gout drug already approved in five Asian markets, less than a year after a $205 million Series A.→

Coverage Timeline

newest first

Jul 22, 2026FUNDINGCrystalys Raises $130M to Push Gout Drug Through Phase 3$130M Series B→

All Coverage

FUNDING· Jul 22, 2026

Crystalys Raises $130M to Push Gout Drug Through Phase 3

FUNDING$130M Series B

Crystalys Raises $130M to Push Gout Drug Through Phase 3

Crystalys Therapeutics raised a $130 million Series B led by Frazier Life Sciences to fund global Phase 3 trials of dotinurad, an oral gout drug already approved in five Asian markets, less than a year after a $205 million Series A.

Jul 22, 2026

Related Companies

Same sector

Attovia Therapeutics Apnimed Braveheart Bio Latigo Biotherapeutics Scribe Therapeutics

Sources & methodologyshow

Where these figures come from

citybizValue Add VC data1 fact

Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.

How we verify data · Suggest a correction